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Abstract
Background: EphB receptors and their ephrin-B ligands play an important role in nervous system development, as
well as synapse formation and plasticity in the adult brain. Recent studies show that intrathecal treatment with
EphB-receptor activator ephrinB2-Fc induced thermal hyperalgesia and mechanical allodynia in rat, indicating that
ephrin-B2 in small dorsal root ganglia (DRG) neurons and EphB receptors in the spinal cord modulate pain
processing. To examine the role of ephrin-B2 in peripheral pain pathways, we deleted ephrin-B2 in Nav1.8+
nociceptive sensory neurons with the Cre-loxP system. Sensory neuron numbers and terminals were examined
using neuronal makers. Pain behavior in acute, inflammatory and neuropathic pain models was assessed in the
ephrin-B2 conditional knockout (CKO) mice. We also investigated the c-Fos expression and NMDA receptor NR2B
phosphorylation in ephrin-B2 CKO mice and littermate controls.
Results: The ephrin-B2 CKO mice were healthy with no sensory neuron loss. However, pain-related behavior was
substantially altered. Although acute pain behavior and motor co-ordination were normal, inflammatory pain was
attenuated in ephrin-B2 mutant mice. Complete Freund’s adjuvant (CFA)-induced mechanical hyperalgesia was
halved. Formalin-induced pain behavior was attenuated in the second phase, and this correlated with diminished
tyrosine phosphorylation of N-methyl-D-aspartic acid (NMDA) receptor subunit NR2B in the dorsal horn. Thermal
hyperalgesia and mechanical allodynia were significantly reduced in the Seltzer model of neuropathic pain.
Conclusions: Presynaptic ephrin-B2 expression thus plays an important role in regulating inflammatory pain
through the regulation of synaptic plasticity in the dorsal horn and is also involved in the pathogenesis of some
types of neuropathic pain.
Background
The Eph receptors and their ephrin ligands, the ephrins,
are the largest family of receptor tyrosine kinases. The
interactions between Eph receptors and their ligands,
classified into A and B-subclasses based on sequence
homology and binding affinity, can initiate bidirectional
signaling [1,2]. Eph receptors have diverse activities on
both neuronal and non-neuronal cells and influence
cell-substrate adhesion, intercellular junctions, cell shape
and cell movement [3]. Eph receptors play essential
roles in nervous system circuit assembly during develop-
ment [4,5] and regulate synaptic function mediated by
NMDA receptors in the adult brain [6]. Several studies
demonstrated that EphB receptors and ephrins play key
roles as modulators of synaptic plasticity in the central
nervous system [7,8].
Recent work using neutralizing receptor bodies
(EphB1/Fc fragments) or stabilized activators (ephrin-
B2/Fc) suggests that Eph receptors and their ligands
also play an important role in pain signaling between
DRG and neurons of the dorsal horn of spinal cord [9].
Ephs/ephrins are also involved in neuropathic pain pro-
cessing. Intrathecal administration of ephrin-B2 siRNA
decreased the expression of ephrin-B2 and mechanical
allodynia after sciatic nerve crush [10]. Song et al.
showed that expression of both ephrin-B1 and EphB1
are increased in the DRG and spinal cord after chronic
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tion of both [11]. EphB1/Fc and EphB2/Fc administra-
tion also prevented hyperexcitability of nociceptive
neurons in the DRG and sensitization of wide dynamic
range neurons in the dorsal horn in a neuropathic pain
model in rat [12]. They later identified EphB1 as the
specific EphB receptor involved in both neuropathic
pain and morphine tolerance dependence using EphB1
knockout mice [13]. They also demonstrated that EphB1
is essential for long-term potentiation between primary
afferent c-fibres and dorsal horn neurons in the spinal
cord [14]. Although these studies suggest that EphB
receptors and their ligands (ephrin-B1 and/or ephrin-
B2) are involved in pain processing in the DRG and
spinal cord, the cell types involved and mechanisms are
still not clear. Ephrin-B1 global null mice are lethal [15].
The signaling mechanisms based on the administration
of ectopic EphB/Fc and ephrin-B2/Fc chimerae remain
uncertain, because over-expression studies may be
unphysiological, whilst blocking receptor bodies may not
completely inhibit signaling.
In the present study, we have investigated the role of
ephrin-B2 mediated signaling in pain pathways by delet-
ing ephrin-B2 from Nav1.8-expressing nociceptors with
the Cre-recombinase-loxP system. By crossing two
floxed ephrin-B2 strains, a floxed exon 1 mouse [16]
and a floxed exon 2 mouse [17] with the Nav1.8 promo-
ter-driven Cre mouse Nav1.8-Cre [18], we generated
ephrin-B2 CKO mice, as the global ephrin-B2 homozy-
gous mutant mice die at E9.5 with severe cardiovascular
defects [19,20]. Here we present an analysis of signaling
to the central nervous system and pain behavior in the
nociceptor-specific ephrin-B2 null mice.
Results
Floxed exon 2 ephrin-B2 is deleted in nociceptors by
Nav1.8-Cre
To generate ephrin-B2 CKO mice, we crossed a floxed
exon 1 ephrin-B2 mouse [16] with the Nav1.8-Cre
mouse line. We genotyped the CKO and littermate con-
trols by PCR. The result shows that the knockout PCR
product was very weak from conditional null mutant
DRG. However, heterozygous global null ephrin-B2
mice derived from crossing with a ROSA-Cre deletor
showed a very strong appropriate PCR product (Addi-
tional file 1, S1). The Cre recombinase gene in the
ephrin-B2 CKO mice was confirmed with PCR and
Southern blot (Additional file 1, S2). We therefore
examined the floxed exon 1 knockout locus with South-
ern blots. The result shows that the exon 1 ephrin-B2
knockout bands (6.1 kb/HindIII and 4.8 kb/HindIII/
EcoRI) were clearly revealed from ephrin-B2 global
knockout mice, but were not found in the exon 1
ephrin-B2 CKO mice (Additional file 1, S3). In terms of
PCR and Southern blot results, the deletion of exon 1
occured in DRG, but the efficiency was very low, prob-
ably because the Nav.1.8 promoter drives Cre expression
much less efficiently than the global Cre promoter, and
some regions adjacent to exon 1 may be masked by reg-
ulatory chromatin proteins.
We therefore tested a floxed exon 2 ephrin-B2 mouse
[17], and crossed the mouse with Nav1.8-Cre. Figure 1A
shows the ephrin-B2 locus, loxP sites and position of
PCR primers. Using PCR analysis, we examined the Cre
excision in CKO mice. The result shows that knockout
band (400 bp) was clearly apparent from DRG DNA in
the CKO mice (Figure 1B). We therefore used the exon
2 ephrin-B2 conditional knockout (Efnb2 CKO) mutant
mice and their floxed exon 2 ephrin-B2 (Efnb2
fl/fl) litter-
mate controls for further experiments.
Ephrin-B2 deletion does not affect either the survival of
DRG neurons or distribution of the nociceptive primary
afferent terminals in the spinal cord
Whole DRG sections were examined to test for effects
of ephrin-B2 deletion on neuronal survival. The sections
were labeled for neuronal markers peripherin and
Figure 1 Exon 2 of ephrin-B2 was deleted in DRG in Efnb2 CKO
mice. (A) Diagram showing the ephrin-B2 wild-type locus, the
targeted locus before and after Cre excision, Nav1.8 wild-type and
Nav1.8-Cre locus. Exons are represented as numbered boxes. The
loxP site (blank triangles) and the PCR primers (black arrows) are
indicated. (B) Genotyping analysis with PCR. The DRGs genomic
DNA from Efnb2 CKO mice, Efnb2
fl/fl controls, heterozygous floxed
exon 2 ephrin-B2 (Efnb2
fl/+) mice and C57BL/6 wild-type (WT) mice
were examined with PCR. The wild-type band (wt), floxed band
(floxed) and Cre band (cre) were amplified with primer sets a/b, a/c
and d/e respectively. The knockout band (ko) was found only from
Efnb2 CKO mutant mice.
Zhao et al. Molecular Pain 2010, 6:77
http://www.molecularpain.com/content/6/1/77
Page 2 of 13neurofilament heavy chain. The result shows that most
small and medium diameter DRG neurons (nociceptors)
were labeled with anti-peripherin antibody in green,
large diameter DRG neurons were labeled with anti-
neurofilament (N200) in red (Figure 2A). There was no
apparent difference between Efnb2
fl/fl controls and
Efnb2 CKO mutant mice. The DRG sections from L5
were also labeled with neuronal marker IB4, anti-CGRP
and anti-neurofilament (N52), and co-labeled with neu-
ron marker bIII tubulin. All the sections from Efnb2
CKO mutants had a normal appearance, with no signifi-
cant difference from Efnb2
fl/fl controls (Figure 2B), and
the proportions of IB4, CGRP and neurofilament (N52)
positive neurons in Efnb2 CKO mice ware similar to the
Efnb2
fl/fl controls (Figure 2C). The spinal cord sections
from lumber 4-5, labeled with IB4 and anti-CGRP, were
used to investigate the distribution of the nociceptive
primary afferent terminals from Efnb2 CKO mutant
mice. The result shows that no significant difference
was found on estimated area of termination or their
staining intensity from the IB4 and CGRP labeling
(Figure 2D).
Ephrin-B2 CKO mutant mice show no gross abnormalities
Efnb2 CKO mutants were healthy, fertile, and apparently
normal. They showed no obvious differences from
Efnb2
fl/fl controls in appearance and spontaneous beha-
vior. Age (8-13 weeks) -matched and sex-mixed Efnb2
CKO mutant mice (n = 9) and Efnb2
fl/fl controls (n = 8)
were weighed and used for von Frey, Randall Selitto,
Hargreaves’, hot plate and cold plate tests. The average
weight was 26.87 ± 1.88 gram (g) (Efnb2 CKO) and
28.4 ± 1.47 g (Efnb2
fl/fl). Motor function of the mice was
examined with a rotarod. The average time that animals
stay on the rod was 241.9 ± 9.8 seconds (sec) (Efnb2
fl/fl)
and 224.6 ± 10.4 sec (Efnb2 CKO). There were no signifi-
cant differences between the two groups either in the
weight (t-test, p = 0.27) or in the time spent on the rod
(t-test, p = 0.13) (Figure 3A).
Ephrin-B2 CKO mutant mice show normal acute pain
behavior
The response to mechanical stimulation was tested by
using von Frey hairs. 50% threshold of paw withdrawal in
response to von Frey hairs was 0.74 ± 0.04 g (Efnb2
fl/fl)
and 0.64 ± 0.05 g (Efnb2 CKO). There was no significant
difference between these two groups (t-test, p = 0.16)
(Figure 3B). To assess the response to noxious mechanical
pressure, the animals were tested with Randall-Selitto
apparatus. The mean of weight that resulted in a withdra-
wal response was 179.3 ± 17.2 g (Efnb2
fl/fl) and 202.7 ±
25.2 g (Efnb2 CKO). No significant difference in weight
applied to the tail was found (t-test, p = 0.43) (Figure 3C).
Acute thermal threshold was examined using Hargreaves’
test. The mean latency of withdrawal of the hindpaw from
a thermal stimulus was 10.5 ± 0.2 sec (Efnb2
fl/fl) and 9.9 ±
0.2 sec (Efnb2 CKO). There was no significant difference
between these two groups (t-test, p = 0.18) (Figure 3D).
Acute thermal threshold was also examined using a hot-
plate. The means latency to withdrawal of a hindpaw at
50°C was 32.2 ± 3.6 sec (Efnb2
fl/fl) and 31.6 ± 1.7 sec
(Efnb2 CKO), at 55°C was 12.8 ± 0.7 sec (Efnb2
fl/fl)
a n d1 4 . 8±0 . 5s e c( E f n b 2C K O ) , respectively. There was
no significant difference between these two groups either
at 50°C (t-test, p = 0.89) or at 55°C (t-test, p = 0.06)
(Figure 3E). Acute thermal threshold was also examined
using a cold-plate. The mean time to a paw lifting and/or
jumping at 0°C was 79.1 ± 7.8 times (Efnb2
fl/fl) in 10 min-
u t e sa n d7 8 . 0±5 . 7t i m e s( E f n b 2C K O ) .T h e r ew a sn o
significant difference between these two groups (t-test,
p=0 . 9 1 )( F i g u r e3 F ) .
Ephrin-B2 CKO mutant mice show deficits in
inflammatory pain
Tonic responses to intraplantar formalin were observed
in formalin test [21]. The first phase (0-10 min) showed
no significant difference in pain behavior between the
two groups, but the second phase (10 - 60 min) was
reduced in Efnb2 CKO mutant mice (t-test, p = 0.048).
The mean numbers of lifting and biting of the injected
paw was 390.3 ± 56.3 sec (Efnb2
fl/fl, n = 8) and 248.6 ±
31.4 sec (Efnb2 CKO, n = 11) (Figure 4A). Interplantar
injection with the inflammatory agent carrageenan leads
to a pronounced thermal hyperalgesia and mechanical
allodynia that were maintained over a period of 24
hours. However there were no significant difference
showing between the ephrin-B2 CKO mice and floxed
littermate controls (Figure 4B and 4C). We also tested
inflammatory pain with CFA model. Thermal and
mechanical responses were recorded at Day 1, 2, 5, 7, 9
and 14 after the CFA injection. Ten Efnb2 CKO mutant
mice and ten Efnb2
fl/fl controls were observed with
Hargreaves and von Frey. Both groups had developed
thermal hyperalgesia and mechanical allodynia 24 hours
after CFA injection (Figure 4D and 4E). Both Efnb2
CKO mice and Efnb2
fl/fl controls show the similar ther-
mal hyperalgesia response (Figure 4D). However, the
Efnb2 CKO mutants displayed overall less mechanical
allodynia and significant differences were recorded from
5 days after injection (two-way ANOVA, p < 0.05)
(Figure 4E).
Ephrin-B2 CKO mutant mice show deficits in neuropathic
pain
The Seltzer model of partial sciatic nerve ligation was
used to assess the alteration in thermal and mechanical
sensitivity characteristic of neuropathic pain. Following
a Seltzer ligature, both thermal hyperalgesia and
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Page 3 of 13Figure 2 Neural marker expression was normal in DRG neurons of ephrin-B2 CKO mice. (A) Whole DRG sections of Efnb2 CKO mutant
mice and Efnb2
fl/fl littermate controls were labeled with anti-peripherin (green) and anti-neurofilament (red) antibodies. The right panels are
merged images of the left and middle panels. (B) DRG sections were also labeled with anti-CGRP (red) and anti-IB4 (red) antibodies, co-labeled
with anti-bIII-tubulin (green). The right panels are erged images of the left and middle panels. (C) The proportions of CGRP, IB4 and
neurofilament (N52) expressing neurons were normal in Efnb2 CKO animals compared to Efnb2
fl/fl littermate controls. (D) Cross section of
lumbar spinal cord (L3 - L5) stained with anti-CGRP (green) antibody and anti-IB4 (red) antibody. In laminae I-II, both CGRP positive terminals and
IB4 positive terminals were identified in the Efnb2 CKO mutant mice and Efnb2
fl/fl littermate controls. Scale bar = 50 μm.
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mals (Figure 4F and 4G). However, deletion of ephrin-
B2 from nociceptors substantially reduced the mecha-
nical allodynia. Efnb2
fl/fl mice showed a substantial
decrease in response threshold, to ~ 15% of baseline
3 days after the surgery. In contrast, Efnb2 CKO mutant
mice maintained a threshold of ~ 70% of baseline (two-
way ANOVA, p < 0.001) (Figure 4G). Also, deletion of
ephrin-B2 from nociceptors reduced thermal hyperalge-
sia. (two-way ANOVA, p < 0.01) (Figure 4F).
c-Fos expression in spinal cord of ephrin-B2 CKO mutants
is diminished in inflammatory pain
Proto-oncogene c-Fos is rapidly and transiently
expressed in the neurons of spinal cord in response to
peripheral noxious stimuli [22,23]. Activation of c-Fos
has been used as a neural marker of pain pathways and
pain intensity [24]. We examined the expression of
c-Fos in the spinal cord after formalin stimulation in the
hindpaw (Figure 5A). The result shows that there were
40.3 ± 3.0 (n = 3) c-Fos positive cell nuclei per semi-
section in the laminae I and II of spinal cord from
Efnb2
fl/fl controls and 29.3 ± 3.1 (n = 3) c-Fos positive
cell nuclei per semi-section in the spinal cord from
Efnb2 CKO mutants, a significant decrease of the for-
malin induced c-Fos expression in the spinal cord from
Efnb2 CKO mutant mice compared to the Efnb2
fl/fl con-
trols (t-test, p = 0.046) (Figure 5B).
NR2B phosphorylation in spinal cord of ephrin-B2 CKO
mutants is lost in some inflammatory pain models
Immunoprecipitation (IP) and Western blot of NR2B
was performed to establish whether formalin treatment
induces tyrosine phosphorylation of NMDA receptor
subunit NR2B, and if the extent of the phosphorylation
is different in Efnb2 CKO mutant mice and Efnb2
fl/fl
controls. Thirty minutes after formalin injection in the
hindpaw proteins were extracted from the dorsal horn in
Figure 3 Acute pain behavior was not affected in ephrin-B2 mutant mice. (A) Rotarod studies showed no motor deficits in Efnb2 CKO
animals. (B) Responses to low-threshold mechanical stimulation by von Frey filaments are normal in Efnb2 CKO mutant mice. (C) Acute
mechanical pressure applied with the Randall Selitto apparatus demonstrated identical behavior in Efnb2 CKO and Efnb2
fl/fl mice. (D) Hargreaves’
apparatus also demonstrates identical latencies of response to thermal stimulation in Efnb2 CKO and Efnb2
fl/fl mice. (E) Supra-spinal reflexes to
heat (50 and 55°C) using the hot plate apparatus demonstrates identical latencies in Efnb2 CKO and Efnb2
fl/fl mice. (F) Cold behavior (number of
liftings) is the same in Efnb2
fl/fl and Efnb2 CKO mice (0°C) using the cold plate apparatus.
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Page 5 of 13Figure 4 Both inflammatory and neuropathic pain behavior are attenuated in ephrin-B2 null mutant mice. (A) Two phases (0 - 10 min,
10 - 60 min) of licking and biting behavior after intraplantar injection of formalin were analyzed, the second phase of which is attenuated in
Efnb2 CKO mutant mice. (B) Intraplantar injection of carrageenan caused identical thermal hyperalgesia in Efnb2
fl/fl controls and Efnb2 CKO mice.
(C) Intraplantar injection of carrageenan caused a long-term mechanical allodynia in both Efnb2 CKO mutants and controls. (D) Intraplantar
injection of CFA caused identical thermal hyperalgesia in Efnb2
fl/fl controls and Efnb2 CKO mutant mice. (E) However, intraplantar injection of
CFA caused a long-term mechanical allodynia that is attenuated after 4 hours in Efnb2 CKO mutants (two-way ANOVA, * p < 0.05). (F) Both
Efnb2 CKO mutant mice and Efnb2
fl/fl controls showed thermal hyperalgesia after sciatic nerve ligation (Seltzer model). However, thermal
hyperalgesia was attenuated in Efnb2 CKO mutants (two-way ANOVA, * p < 0.05). (G) Sciatic nerve ligation following the Seltzer procedure
caused a long-lasting mechanical allodynia that was attenuated after 5 days of surgery in Efnb2 CKO mutant mice (two-way ANOVA, * p < 0.05).
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Page 6 of 13spinal cords (L3-L5) and immunoprecipitated with NR2B
antibody. The result shows that the relative level of phos-
phorylated NR2B in dorsal horn from the Efnb2
fl/fl con-
trol mice was remarkably increased (184.2 ± 17.1%) after
formalin injection. However, there was no significant
increase of NR2B phosphorylation in dorsal horn from
the Efnb2 CKO mutant mice (93.1 ± 20.7%) (Additional
file 1, S4A). NR2B receptor phosphorylation was also
detected after CFA injection in the hindpaw (Additional
file 1, S4B). The relative level of phosphorylated NR2B
was significantly increased in Efnb2
fl/fl controls (138.4 ±
13.8%) 24 hours after CFA injection, but not in Efnb2
CKO mice (108.3 ± 13.0%) (Additional file 1, S4B).
Microglial activation in spinal cord is attenuated in
ephrin-B2 CKO mutant mice, but GFAP and ATF3
immunoreactivity are normal in DRG
To investigate the state of glial cell activation in the spinal
cord after nerve injury, microglial cells were identified by
immunoreactivity for ionized calcium binding adaptor
molecule 1 (Iba1) and quantified throughout the lumbar
spinal cord. There were similar number of positvie micro-
glial cells in sham animals (0.13 ± 0.04, Efnb2
fl/fl controls;
0.02 ± 0.02, Efnb2 CKO) in 10
4 μm
2of the spinal cord sec-
tion (Figure 6A and 6B). Increasing microglia activation
was observed in the ipsilateral dorsal horn of the spinal
cord from day 3 onwards following the nerve injury. The
number of activated microglia cells per 10
4 μm
2 (see
method) was 4.7 ± 0.8 (Day 3), 9.1 ± 0.3 (Day 7), 5.1 ± 0.2
(Day 14), 2.2 ± 0.1 (Day 26) in Efnb2
fl/fl controls, and 4.9 ±
0.6 (Day 3), 6.2 ± 0.1 (Day 7), 3.4 ± 0.4 (Day 14), 1.4 ± 0.2
(Day 26) in Efnb2 CKO mice respectively. Compared to
Efnb2
fl/fl controls microglial activation in the dorsal horn
was significantly reduced seven days after nerve ligation in
Efnb2 CKO mutant mice. In the contralateral side,
although there was up-regulation of the microglia activa-
tion from day 3 onwards, the level is far lower than in the
ipsilateral dorsal horn (data not shown). We also exam-
ined levels of immunoreactivity for glial fibrillary acidic
protein (GFAP) in the spinal cord. After partial ligation of
sciatic nerve, the expression of GFAP positive cells in the
ipsilateral side of spinal cord significantly increased in
Efnb2
fl/fl controls and Efnb2 CKO mutant mice compared
to sham controls (Additional file 1, S6). However, the
increased immunoreactivity of GFAP positive cells in
spinal cord was similar between Efnb2 CKO mice and
Efnb2
fl/fl controls. Expression of Activating transcription
factor 3 (ATF3) in the L5 DRG was also investigated 7
days after partial ligation of sciatic nerve. The number of
ATF3 positive nuclei obviously increased in contralateral
L5 DRGs in both Efnb2
fl/fl controls (38.1 ± 5.5%) and
Efnb2 CKO mice (34.7 ± 8.3%) (Additional file 1, S5).
Figure 5 c-Fos expression was attenuated in the spinal cord in ephrin-B2 conditional mutant mice after formalin injection in the
hindpaw. (A) Representative immunostaining for c-Fos in superficial laminae I, II after formalin injection. The right hemicord is showing the cord
ipsilateral to the injection of formalin or saline. (B) Cell counting for c-Fos positive nuclei in the dorsal horn. Compared to Efnb2
fl/fl control mice,
the number of positive c-Fos nuclei in the ipsilateral side in Efnb2 CKO mutants is significantly reduced after formalin injection. Scale bar = 100
μm. All data presented as means ± SEM; using students t-test, * p < 0.05.
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Page 7 of 13However, there is no significant difference between the
two groups (t-test, p = 0.75).
Discussion
The present studies demonstrate that presynaptic
ephrin-B2 expressed by Nav1.8+ nociceptors has an
important role in regulating to the central nervous
system in conditions of inflammatory and neuropathic
pain. Previous studies, consistent with these data, could
not define the cell types involved, or distinguish between
pre- or postsynaptic activation of EphB receptors
[12,13]. The exclusive pre-synaptic localization of the
ephrin-B2 deletion avoids this ambiguity. These results
also underline the importance of avoiding floxed exon 1
Figure 6 Increase of immunoreactivity for Iba1 was attenuated in the spinal cord in ephrin-B2 conditional mutant mice in a Seltzer
neuropathic pain model. (A) Representative immunostaining for Iba1 in superficial laminae I, II after sciatic nerve partial ligation (Seltzer
model). The right hemicord is showing the cord ipsilateral to the sciatic nerve partial ligation. (B) Cell counting for Iba1 positive cells in the
dorsal horn. The microglia were activated after sciatic nerve partial ligation in both Efnb2
fl/fl controls and Efnb2 CKO mice. However, the increase
of immunoreactivity for Iba1 was attenuated in Efnb2 CKO mice. Data shown as mean ± SEM, Scale bar = 100 μm. Using students t-test, * p <
0.05; ** p < 0.01.
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conditional knockout mice. Regulatory regions that are
associated with transcription factors and the complex
machinery involved in controlling gene expression may
cause loxP sites to be masked and contribute to the low
frequency of DNA excision that we found with floxed
exon 1 ephrin-B2 mice. Using identical Cre mice with
floxed exon 2 ephrin-B2 mice, gene excision was highly
efficient, and allowed us to analyse the role of ephrin-B2
in damage to the central nervous system.
Earlier studies have shown that neutralizing Eph
receptor bodies could partially reverse inflammatory
pain [9]. Although it is technically difficult to use such
approaches to examine long term pain conditions such
as neuropathic pain, Eph receptor bodies could prevent
or reverse thermal and mechanical hyperalgesia in a
chronic constriction injury model of neuropathic pain
[12]. These studies implicated EphB/ephrin-B interac-
tions in the onset and maintenance of both inflamma-
tory and neuropathic pain. Kobayashi et al, who showed
ephrin-B2 expression up-regulation in DRG and spinal
cord neurons in a model of neuropathic pain (spinal
nerve ligation), prevented the development of mechani-
cal allodynia with the intrathecal infusion of ephrin-B2
silencing RNAs [10]. This method does not allow us to
distinguish between pre- and post-synaptic effects Using
conditional knockouts in Nav1.8 nociceptors avoids
these difficulties of interpretation.
Ephrin-B2 is involved in intracellular signaling in a
range of non-neuronal and neuronal tissues [3,25-27].
Signaling involves small GTPases of the Rho and Ras
family the Jak/Stat pathway and the PI3K pathway, whilst
reverse signaling involving tyrosine phosphorylation of
the ephrin-B2 ligand may also occur [28]. Alterations in
the actin cytoskeleton have been associated with changes
in synaptic plasticity [29,30]. In addition, within the ner-
vous system, regulation of NMDA receptors through
ephrin-B2 induced phosphorylation has been described
[31]. Slack et al. also demonstrated that intrathecal infu-
sion of ephrin-B2 in adult rats induces NR2B phophory-
lation, probably via src family kinases, and EphB1
receptor body infusion prevents NR2B phophorylation in
the carrageenan model of inflammation [32].
The deficits in pain induced by tissue damage (forma-
lin model) are associated with a diminished NMDA
receptor NR2B tyrosine phosphorylation and a lower
level of c-Fos expression in the dorsal horn of the spinal
cord. These suggest that, following tissue injury, activa-
tion of post-synaptic EphB receptors by pre-synaptic
ephrin-B2 is necessary to induce increased in Ca
++ cur-
rents via NMDA receptors, regulated by NR2B phos-
phorylation, and consequent spontaneous pain behavior.
The mechanism underlying the enhanced signaling
mediated by ephrin-B2 in inflammation and tissue injury
is likely to reflect increased ephrin-B2 protein expres-
sion in sensitized pain states. In other cell types, for
example bone, the induction of ephrin-B2 expression
through the activation of transcription factor NFAT has
been documented [33]. Many inflammatory mediators -
for example bradykinin - are also known to induce
NFAT expression, so it is likely that enhanced expres-
sion of ephrin-B2 results in NMDA receptor NR2B
phosphorylation that potentiates synaptic efficacy and
increase calcium flux. Increased noxious input into the
dorsal horn reflected by enhanced c-Fos expression in
inflammatory pain states is diminished in the ephrin-B2
conditional knockout mice.
There is also evidence that in neuropathic pain caused
by nerve crush, ephrin-B2 expression is enhanced with
similar consequences for synaptic signaling [10]. In
many neuropathic pain models there is also an inflam-
matory pain component. We found that in the Chung
model of neuropathic pain, the cell types involved were
not principally Nav1.8-positive neurons, whilst in the
Seltzer model, these cells do contribute to some extent
to neuropathic pain. In the present studies the Seltzer
neuropathic pain models showed deficits in the absence
of ephrin-B2, although this was not reflected in ATF3
expressing damaged cells, providing further support to
the hypothesis that ephrin-B2 present in DRG cells sig-
nals to postsynaptic neurons to induce neuropathic
pain. Interestingly, the recruitment of activated micro-
glia, considered an important element in the induction
of neuropathic pain was lowered at seven days post-
injury, suggesting that signals from ephrin-B2 expressing
nociceptors mediated by dorsal horn neurons result in
some form of recruitment of activated microglia within
the spinal cord. However, the sensitized pain state asso-
ciated with nerve damage arises considerably before this,
suggesting that ephrin-B2 signaling is not the principal
mechanism for the initial recruitment of activated
microglia.
Conclusions
In summary, the present conditional ephrin-B2 gene
deletion studies confirm a significant role for ephrin-B2
signaling in regulating pain thresholds in inflammatory
and neuropathic pain. The mechanisms involved include
NMDA receptor phosphorylation as first described in
cultured cortical and hippocampal neurons [31] with
subsequent enhanced nociceptive input into the dorsal
horn. However, in the hippocampus (or elsewhere) a
role for presynatic ephrin-B2 has still not been conclu-
sively demonstrated [27], therefore this is the first study
to provide evidence in favor of this role. Given the
broad range of physiological systems in which ephrin
plays an important regulatory role, it is unlikely that tar-
geting ephrin mediated in peripheral pain pathways will
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Nonetheless this sensory system provides an excellent
model to relate molecular changes in synaptic efficacy
to behavioral effects.
Methods
Generation of Nav1.8-specific ephrin-B2 null mutant mice
To generate nociceptor-specific ephrin-B2 null mutants,
two floxed ephrin-B2 lines; containing either floxed
exon 1 [16] or floxed exon 2 [17], were crossed with the
Nav1.8-Cre mice [18] to effect ephrin-B2 gene ablation
in a defined subset of sensory neurons. The study popu-
lation contained the homozygous floxed ephrin-B2 gene
and one copy of the Nav1.8-Cre allele, whilst homozy-
gous floxed ephrin-B2 littermates were used as controls.
Mice were housed with a 12-hr light: 12-hr (lights on at
07:00) dark cycle and maintained under standard condi-
tion (21 ± 1°C, food and water ad libitum).
Genotyping with PCR
DNA was isolated from ear or DRGs. The ephrin-B2
exon 1 wild-type fragment (627 bp), floxed exon 1 frag-
ment (700 bp) and exon 1 mutant fragment (328 bp)
were detected by PCR with primer set: a) 5’-AGG-
GACGCGCAGGGTGAG-3’;b )5 ’-CAATGTGTGTCTG-
TAGCCCCGTTA-3’ (Additional file 1, S1). The ephrin-
B2 exon 2 wild-type fragment (262 bp), floxed exon 2
fragment (~380 bp) and exon 2 mutant fragment (~320
bp) were detected by PCR with primer: a) 5’-CTTCAG-
CAATATACACAGGATG-3’;b )5 ’-TGCTTGATT-
GAAACGAAGCCCG-3’;c )5 ’-AATACTGTTACTA
CAGGGTCC-3’ (Figure 1A). The Nav1.8-Cre fragment
(461 bp) was detected by PCR with primer: d) 5’-TGTA-
GATGGACTGCAGAGGATGGA-3’;e )5 ’-AAATGTTG
CTGGATAGTTTTTACTGCC-3’ (Figure 1A).
Genotyping with southern blot
A3 ’ external probe (709 bp), which was amplified by
PCR from C57BL/6 mouse genomic DNA with a for-
ward primer (5’-GCTTGAGTTGAAACGCGGAGG-3’)
and a reverse primer (5’-CACCTCGCTGCTGATG-
GAGA-3’), was used to detect the Nav1.8 allele (Addi-
tional file 1, S2). A 5’ arm external probe (790 bp),
which was amplified by PCR from C57BL/6 mouse
genomic DNA with a forward primer (5’-ATG-
TAGGTTTGCACTGGCGAAT-3’) and a reverse primer
(5’-GAGGTATTGTGGTGGGCAAATC-3’), was used to
detect the ephrin-B2 allele (Additional file 1, S3). The
probes were labeled with [a-
32P]dATP (Amersham)
using Prime-It II Random Primer Labeling Kit (strata-
gen) and purified with QIAquick Nucleotide Removal
Kit (Qiagen). Southern blot analyses were carried out by
standard protocol [34]. Briefly, DNA was extracted from
tail or DRG. 10 μg restricted DNA was separated on a
0.7% agarose gel, and transferred onto Hybond-N nylon
membrane (Amersham). Filters were hybridized with
32P-radiolabeled 5’ probe or the 3’ probe, then were
washed at decreasing concentrations of SSC with the
final wash being in 0.1× SSC/0.1% SDS at 65°C and
exposed to X-R Kodak film for 48 hours. Southern blot
hybridization of BamHI-digested genomic DNA with
the 3’ probe yielded a 6.7 kb wild-type band and 7.2 kb
targeted band (Additional file 1, S2). Southern blot
hybridization of HindIII-digested genomic DNA with
the 5’ p r o b ey i e l d e da6 . 3k bw i l d - t y p eb a n d ,4 . 1k b
floxed band and 6.1 kb knockout band. Southern blot
hybridization of HindIII/EcoRI-digested genomic DNA
with the 5’ probe yielded a 4.2 kb wild-type band, 4.1 kb
floxed band and 4.8 kb knockout band (Additional
file 1, S3).
Immunohistochemical analysis
Mice were deeply anesthetised with pentobarbital (140
mg/kg) and transcardially perfused with heparinised sal-
ine (0.9% NaCl) followed by 4% paraformaldehyde (PFA)
in 0.1 M phosphate buffer (PB), pH7.4. The lumbar
spinal cords and DRGs were dissected and post-fixed in
4% PFA overnight at 4°C. The tissue was transferred
into 20% sucrose in PB for 24 hours at 4°C, and then
blocked in OCT compound (BDH Essex, UK) in liquid
nitrogen. Transverse sections were cut at 11 μm (DRGs)
and 15 μm (lumbar cords) thickness on a Cryostat, and
then mounted onto Superfrost plus slides. The slides
were washed three times for 5 min each with 0.01 M
phosphate buffer solution (PBS). After blocking in 10%
goat serum in PBS for 1 hour, the sections were incu-
bated with the primary antibodies overnight at room
temperature. After three times washes with PBS, bound
primary antibodies were detected by incubating with the
secondary antibodies at room temperature for 2 hours.
The slides were then washed with PBS for three times
and mounted using Fluorsave. The following primary
antibodies were used: rabbit anti CGRP (1:2000, Sigma
C8198 ); lectin IB4-biotin (1:500, Sigma L 2140); rabbit
anti neurofilament 200 (N200) (1:1000, Sigma, UK,
N4142); mouse anti bIII tubulin (1:1000, Abcam
Ab7751); rabbit anti c-Fos (1:2500, Calbiochem); rabbit
anti Iba1 (1:1000, Wako); rabbit anti GFAP (1:1000,
Dako cytomation, Denmark); rabbit anti ATF3(1:500,
Santa Cruz sc-188). The following secondary antibodies
were used: goat anti rabbit IgG Alexa fluor 488 (1:1000,
Molecular Probes A11034); goat anti rabbit IgG Alexa
fluor 546 (1:1000, Molecular Probes A11035); extra ava-
din TRITC (1:500, Sigma E3011); goat anti mouse IgG
Alexa fluor 488 (1:1000, Molecular probes A11029);
donkey anti goat TRITC (1:200, Stratech 705-025-147).
All antibodies were diluted to working concentrations
with PBS with 1% (w/v) Triton X-100 and 0.01% (w/v)
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photographed using a Zeiss Axionplan 2 microscope
and a Zeiss Axiocam HR. Photo acquisition used Axiovi-
sion 40LE version 4.6 software. All neuronal cells with a
clear nuclear profile in DRGs were counted using the
ImageJ image processing and analysis program. For ana-
lysis of the nociceptive terminal staining (CGRP and
IB4) in the spinal cord, the area and intensity of the
immunoreactive positive fibres were measured. For ana-
lysis of the GFAP staining, quantitative assessment of
immunoreactivity was carried out by determining the
immunofluorescence intensity within a fixed area of
the dorsal horn. Five L4-5 sections from each animal
were chosen at random with the treatment blinded. 4
boxes measuring 10
4 μm
2 were placed onto areas of the
lateral, central and medial dorsal horn. Mean grey inten-
sity of this area was determined using KS300 software
(Axiovision software).
Behavioral analysis
All behavioral tests were approved by the United Kingdom
Home Office Animals (Scientific Procedures) Act 1986
and performed in a Home Office designated room at 22 ±
2°C. Experiments were performed on animals of at least
8 weeks of age as described [35] in rotarod, Hargreaves’
apparatus, hotplate, von Frey, Randall-Selitto, and thermal
hyperalgesia model induced by carrageenan. The experi-
menters were blind to the genetic status of test animals.
The Complete Freund’s Adjuvant (CFA, Sigma) inflamma-
tory model were performed by injecting 20 μl of CFA into
the plantar surface of the left paw. The Formalin test was
performed by intraplantar injections of 20 μl of 5% forma-
lin. The mice were observed for 60 minutes and the time
spend biting and licking the injected paw were monitored.
The result was categorized into two phases, the first phase
lasting 0 - 10 minutes and the second phase 10 - 60 min.
Cold plate behavior was performed as described [36]. We
used the Seltzer model to test neuropathic pain. Baseline
responses for mechanical and thermal stimulation were
obtained according to the protocols for von Frey and Har-
greave’s methods. Animals were anaesthetised using
Halothane. An incision was made in the skin of the upper
left leg and blunt scissors were used to part the muscle
layers to access the sciatic nerve. A tight ligation of
between 1/2 - 1/3 of the nerve was made using 6 - 0 mer-
silk suture (Ethicon, UK). The skin was closed using 4 - 0
mersilk sutures (Ethicon, UK). Responses to mechanical
stimulation and thermal stimulation were assessed with
von Frey filaments and Hargreaves’ at 3, 5, 7, 14 and 21
days after surgery.
c-Fos immunohistochemistry
Two hours after intraplantar injections of 20 μlo f5 %
formalin in right hind paw, the ephrin-B2 CKO mice
and floxed littermates were deeply anaesthetized and
perfused and the sections of spinal cord were stained
with anti c-Fos antibody as described above. The level
of immunoreactive c-Fos expression was counted in the
ipsilateral dorsal horn region to the formalin or saline
injection in laminae I and II. And the experimenters
were blind to the genetic status of test animals.
IP and western blots
Lumber dorsal horn tissue was used for the detection of
NR2B phosphorylation after formalin or CFA injection.
As described previously [32],m i c ew e r ea n e s t h e t i z e d
with pentobarbital (140 mg/kg) and the spinal cords
were rapidly obtained by hydraulic extrusion. The dorsal
horns of the lumbar enlargement were dissected out on
ice and were then immediately snap-frozen on liquid
nitrogen. They were homogenized in ice-cold modified
RIPA lysis buffer containing protease and phosphatase
inhibitors (150 mM NaCl, 50 mM Tris, pH 8.0, 1 mM
EDTA, 1% v/v Nonidet P-40, 0.5% SDS, 1 mM phenyl-
methanesulfonyl fluoride, 5 mM NaF, 1 mM NaVO4,
10 μg/ml each antipain, leupeptin and pepstatin). The
samples were left to homogenize for 2 hours under
rotating agitation. The extracts were centrifuged and the
supernatant retained. 1 mg of total protein was added to
5 μgo fg o a ta n t i - N R 2 B( S a n ta Cruz) antibody and
gently shaken overnight at 4°C. Protein-G sepharose
beads were added to the samples and gently shaken for
2 hours at 4°C. Beads were then rinsed in lysis buffer
and boiled in loading buffer. Proteins were separated by
10% SDS-PAGE and transferred onto PVDF membrane
as described [35]. The membranes were blocked in 5%
BSA in TBST (150 mM NaCl, 25 mM Tris-HCl pH 7.6,
3 mM KCl, 0.1% Tween 20) and were incubated in
mouse anti p-Tyr (1:2000; Santa Cruz) and rabbit anti
NR2B (1:1000, Upstate,) at 4°C overnight. Blot was
washed in TBST and incubated with goat anti mouse
Alexa 680 (1:20000, Invitrogen) and donkey anti rabbit
IR 800 (1:20000, LiCor Biosciences UK) at room tem-
perature for 1 hour. All antibodies were diluted in
TBST. Protein bands were visualized and analysed using
the Li-Cor Odyssey Infrared Imaging System (Li-Cor
Biosciences UK, Odyssey 2.0).
Microglia and astrocyte activation in the spinal cord
Immunohistochemical techniques were used to deter-
mine the occurrence of microglia and astrocyte activa-
tion in the dorsal horn. At day 3, 7, 14 and 26 after
partial ligation of the sciatic nerve (Seltzer model), mice
were perfused and the sections of spinal cord were
stained with anti Iba1 antibody and anti GFAP antibody
as described above. We used quantitative image analysis
of immunoreactivity for Iba1, the expression of which is
upregulated following activation of microglia, as a
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animal were chosen at random with the treatment
blinded. 4 boxes measuring 10
4 μm
2 were placed onto
areas of the lateral, central and medial dorsal horn. The
mean number of positive cells was determined within
this area [37]. For GFAP staining, quantitative assess-
ment of immunoreactivity was carried out by determin-
ing the immunofluorescence intensity within a fixed
area of the dorsal horn. Five L4-5 sections from each
animal were chosen at random with the treatment
blinded. 4 boxes measuring 10
4 μm
2 were placed onto
areas of the lateral, central and medial dorsal horn.
Mean grey intensity of this area was determined using
KS300 software (Axiovision software).
Expression of ATF3 in DRG
Seven days after partial ligation of the sciatic nerve
(Seltzer model), the ephrin-B2 CKO mice and floxed lit-
termates were perfused. DRG sections were then stained
with anti ATF3 antibody as described above. All neuro-
nal cells with a clear nuclear profile were counted using
the ImageJ image processing and analysis program. Five
L5 DRG sections from each animal were chosen at ran-
dom with the treatment blinded. All cells stained with
the general neuronal marker bIII tubulin and anti ATF3
antibody were counted. The percentage of ATF3 posi-
tive neurons in the DRG was then calculated [38,39].
Statistical Analysis
All data are presented as mean ± SEM. Data were
assessed for normality, and normally distributed data
sets were compared with two-way analysis of variance
(ANOVA). Non-normal data were assessed with Stu-
dent’su n p a i r e dt - t e s t .p<0 . 0 5w a sr e g a r d e da ss i g n i f i -
cant. All calculations were done using SigmaStat 3.5.
Additional material
Additional file 1: Supplemental material.
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